Dr. James Pinkerton is a Research Associate in the Respiratory Pharmacology group within the National Heart & Lung Institute.
James completed his PhD at the University of Newcastle, Australia in 2018, where he was focused on elucidating the mechanisms associated with severe, steroid-resistant asthma. During this time he established a novel high fat diet-induced model of steroid-resistant asthma to help understand the mechanisms driving this unique asthmatic endotype.
James' currently works with the Imperial College AstraZeneca site team and which is focused on investigating novel therapeutic targets in respiratory models of disease for potential treatment in asthma, COPD, IPF and other severe respiratory conditions.
et al., 2020, Human beta-defensin-2 suppresses key features of asthma in murine models of allergic airways disease, Clinical and Experimental Allergy, Vol:51, ISSN:0954-7894, Pages:120-131
et al., 2020, Crucial role for lung iron level and regulation in the pathogenesis and severity of asthma., European Respiratory Journal, Vol:55, ISSN:0903-1936, Pages:1-14
et al., 2020, Critical role for iron accumulation in the pathogenesis of fibrotic lung disease, Journal of Pathology, Vol:251, ISSN:0022-3417, Pages:49-62
et al., 2020, Modelling IPF-associated chronic cough: role for oxidative stress?, The 2020 ERS International Congress, European Respiratory Society, Pages:1-2, ISSN:0903-1936
et al., 2020, Profiling the impact of two JAK inhibitors in a pre-clinical model of allergic asthma, EUROPEAN RESPIRATORY SOC JOURNALS LTD, ISSN:0903-1936